Telomir Pharmaceuticals (NASDAQ: TELO) announced the publication of peer-reviewed preclinical data in Advances in Redox Research demonstrating that Telomir-Zn delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. The findings include reduced oxidative stress, lower hepatic copper burden, and improved liver function markers, supporting the biological activity of Telomir-Zn in Wilson’s disease.
This research expands the company’s scientific validation as it advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation. The data underscore the potential of Telomir-Zn to address fundamental mechanisms implicated in both cancer and degenerative diseases, such as metal homeostasis and redox balance.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic mechanisms. The company’s lead program, Telomir-1 (Telomir-Zn), has shown activity in preclinical studies involving intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. For more information, visit the company’s newsroom at https://ibn.fm/TELO.
The full press release is available at https://ibn.fm/fOSNo. These results highlight the potential of Telomir-Zn to treat Wilson’s disease, a genetic disorder characterized by copper accumulation, and reinforce the platform’s versatility.
